These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23986641)

  • 21. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma.
    Arai H; Abe T; Takayama H; Toyoda M; Ueno T; Kakizaki S; Sato K
    Hepatol Res; 2015 Jun; 45(6):663-6. PubMed ID: 25132539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.
    Oguro S; Hashimoto S; Tanaka T; Inoue M; Nakatsuka S; Kuribayashi S; Asakura K; Kawachi S; Tanabe M; Kitagawa Y; Ebinuma H; Saito H; Hibi T
    Jpn J Radiol; 2012 Nov; 30(9):735-42. PubMed ID: 22923183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
    Matsumoto T; Ichikawa H; Imai J; Hayashi T; Tomita K; Mine T; Kojima S; Watanabe N; Hasebe T
    Anticancer Res; 2017 Jun; 37(6):3183-3187. PubMed ID: 28551662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial.
    Otsuji K; Takai K; Nishigaki Y; Shimizu S; Hayashi H; Imai K; Suzuki Y; Hanai T; Ideta T; Miyazaki T; Tomita E; Shimizu M; Moriwaki H
    Hepatol Res; 2015 May; 45(5):514-22. PubMed ID: 24961745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
    Imai Y; Chikayama T; Nakazawa M; Watanabe K; Ando S; Mizuno Y; Yoshino K; Sugawara K; Hamaoka K; Fujimori K; Inao M; Nakayama N; Oka M; Nagoshi S; Mochida S
    J Gastroenterol; 2012 Feb; 47(2):179-86. PubMed ID: 21976133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.
    Zheng L; Li HL; Guo CY; Luo SX
    Korean J Radiol; 2018; 19(2):237-246. PubMed ID: 29520181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognosis of patients with hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization: risk factors for one-year recurrence and two-year mortality (preliminary data).
    Matsuda M; Omata F; Fuwa S; Saida Y; Suzuki S; Uemura M; Ishii N; Iizuka Y; Fukuda K; Fujita Y
    Intern Med; 2013; 52(8):847-53. PubMed ID: 23583987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
    Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
    Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin.
    Nishikawa H; Inuzuka T; Takeda H; Nakajima J; Sakamoto A; Henmi S; Ishikawa T; Saito S; Kita R; Kimura T; Osaki Y; Koshikawa Y
    Case Rep Oncol; 2011 May; 4(2):327-35. PubMed ID: 21738504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.
    Yodono H; Matsuo K; Shinohara A
    Anticancer Drugs; 2011 Mar; 22(3):277-82. PubMed ID: 21360850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence.
    Murakami T; Ishimaru H; Sakamoto I; Uetani M; Matsuoka Y; Daikoku M; Honda S; Koshiishi T; Fujimoto T
    Cardiovasc Intervent Radiol; 2007; 30(4):696-704. PubMed ID: 17497071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the antitumor efficacy of transcatheter arterial chemoembolization with a miriplatin-iodized oil suspension and a cisplatin-iodized oil suspension for hepatocellular carcinoma.
    Ueda T; Murata S; Yasui D; Mine T; Kumita S
    Hepatol Res; 2013 Oct; 43(10):1071-7. PubMed ID: 23905645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: Retrospective comparison with conventional super-selective TACE.
    Irie T; Kuramochi M; Kamoshida T; Takahashi N
    Hepatol Res; 2016 Feb; 46(2):209-14. PubMed ID: 26224032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma.
    Kamimura K; Suda T; Tamura Y; Takamura M; Yokoo T; Igarashi M; Kawai H; Yamagiwa S; Nomoto M; Aoyagi Y
    BMC Gastroenterol; 2012 Sep; 12():127. PubMed ID: 22994941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial chemoembolization with miriplatin-lipiodol emulsion for neuroendocrine metastases of the liver.
    Iwazawa J; Ohue S; Yasumasa K; Mitani T
    World J Radiol; 2010 Dec; 2(12):468-71. PubMed ID: 21225002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
    Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
    AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone.
    Smolock AR; Cristescu MM; Hinshaw A; Woo KM; Wells SA; Ziemlewicz TJ; Lubner MG; Dalvie PS; Louis Hinshaw J; Brace CL; Ozkan OS; Lee FT; Laeseke P
    Abdom Radiol (NY); 2018 Sep; 43(9):2497-2504. PubMed ID: 29450606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules.
    Kawamura Y; Ikeda K; Fujiyama S; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Hepatol Res; 2017 Mar; 47(4):338-346. PubMed ID: 27249401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.